Curatis Unveils Corticorelin and Eyes $1 Billion PTBE Market

Curatis Holding AG has identified Corticorelin as the active substance in its C-PTBE-01 drug, aimed at treating peritumoral brain edema (PTBE) associated with brain tumors. A new study indicates a significantly larger target patient group, with over 150,000 in the US and 500,000 globally. This discovery positions Curatis for potentially over USD 1 billion of market opportunity.

Corticorelin has shown a potential to reduce or replace corticosteroid use, mitigating severe side effects and enhancing patient quality of life. It may also maintain the efficacy of cutting-edge cancer therapies by reducing glucocorticoid-related interference.

Curatis is filing for an FDA meeting in Q2 2025 to discuss a Phase 3 trial, scheduled for 2026. The company has strengthened its team with Dr. Kirsty Crame as Chief Medical Officer and Dr. Timm Trenktrog as Head of Chemistry, Manufacturing, and Controls.